Natural killer cell lymphoma/leukemia: pathology and treatment.
Malignancies arising from cells of putative natural killer (NK) cell origin have increasingly been recognized as distinct clinicopathological entities. These malignancies are marked by tumour cells with NK cell characteristics, including the immunophenotype of CD2+, surface CD3-, cytoplasmic CD3 epsilon+, CD7 +/-, and CD56+, and the genotype of germline T cell receptor gene. A consistent association with monoclonal Epstein-Barr virus infection in the tumour cell has been observed. These tumours are now regarded as putative NK cell lymphoma/leukemia. Pathologically, tumour cells show variable cytological appearances, with frequent angiocentricity and angioinvasion, associated with zonal necrosis. Clinically, most cases occur in the nasal area and upper aerodigestive tract. However, occurrence in non-nasal sites such as the skin, gastrointestinal tract and testis is also observed. A particularly aggressive form of NK lymphoma/leukemia presents fulminantly as disseminated disease sometimes with a leukemic phase. All types of NK lymphoma/leukemia have an extremely poor prognosis with a median survival of less than a year. New modalities of treatment, including the use of high dose chemotherapy and stem cell rescue may be needed to improve treatment outcome.
Kwong
Y L
YL
University Department of Medicine, Queen Mary Hospital, Hong Kong.
Chan
A C
AC
Liang
R H
RH
D004279:DNA, Viral / Q000737:chemistry; D006103:Granuloma, Lethal Midline / Q000473:pathology / Q000628:therapy; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D017403:In Situ Hybridization; D007694:Killer Cells, Natural / Q000473:pathology*; D007945:Leukemia, Lymphoid / Q000473:pathology* / Q000628:therapy; D008223:Lymphoma / Q000473:pathology* / Q000628:therapy; D009669:Nose Neoplasms / Q000473:pathology / Q000628:therapy
D004279:DNA, Viral